


Målgruppen för symposiet är neurologer och ST-läkare som möter/behandlar patienter med MS.

Välkommen till det nationella symposiet

Fokus Neurologi – MS

25 mars 2021

WEBINAR



Scanna QR-koden och anmäl dig till detta webinar

<https://bit.ly/fokus-neurologi-2021-reg>

Programkommitté & moderatorer:

JAN LYCKE | Professor, MS Centrum, Sahlgrenska Universitetssjukhuset

LOU BRUNDIN | Professor, Neurologikliniken/KI, Karolinska Universitetssjukhuset

CHARLOTTE DAHLE | Docent, Klinisk Immunologi/Neurologiska kliniken, Linköpings Universitetssjukhus

Föreläsare:

MARKUS AXELSSON | MD, PhD, MS Centrum, Sahlgrenska Universitetssjukhuset, Göteborg

MARTIN KERSCHENSTEINER | Prof. Dr., Deputy Director of the Biomedical Center of the LMU München, Tyskland

JOÃO CERQUEIRA | M.D., PhD, Associated Professor at Minho University; Head of MS Clinic in Hospital de Braga, Portugal

FOKUS NEUROLOGI - MS

Moderatorer: Jan Lycke, Lou Brundin, Charlotte Dahle

15:30	CHECK-IN TILL MÖTET	16:30–16:40	BENSTRÄCKARE
15:45–15:50	Välkommen Christina Gip, Biogen	16:40–17:00	Pathogenetic mechanisms of neurodegeneration in MS Martin Kerschensteiner, München, Tyskland
15:50–15:55	Inledning av programkommittén Jan Lycke, Lou Brundin, Charlotte Dahle	17:00–17:10	Frågestund Programkommittén modererar
15:55–16:15	Hur vet jag när patienten övergår i sekundärprogressiv fas vid MS? Markus Axelsson, Sahlgrenska Universitetssjukhuset, Göteborg	17:10–17:30	Samband och skillnader mellan kognitiv dysfunktion, MS fatigue och depression João Cerqueira, Braga, Portugal
16:15–16:20	Frågestund Programkommittén modererar	17:30–17:40	Frågestund Programkommittén modererar
16:20–16:30	Programkommittén diskuterar. Hur gör vi med antiinflammatorisk behandling vid degeneration Jan Lycke, Lou Brundin, Charlotte Dahle	17:40–17:50	Summering och avslut av programkommittén Jan Lycke, Lou Brundin, Charlotte Dahle
		17:50	MÖTET AVSLUTAS

In accordance with data protection law, Biogen Sweden, Kanalvägen 10A 19461 Upplands Väsby, ("Biogen") processes personal data we collect from you in order to administrate the meeting and fulfil tax accounting and tax regulations. Such collection is necessary to provide you with this service and our processing is in Biogen's legitimate interest as a pharmaceutical company. Where necessary, Biogen may transfer your personal data to other companies in its group and may also engage third party services providers (e.g. IT service providers) to process your personal data on its behalf. Such parties may be located outside Europe, but Biogen will ensure that all recipients are contractually (e.g. by Standard Contractual Clauses) and/or legally obliged to comply with privacy standards in accordance with data protection law. Biogen retains your personal data for no longer than is necessary for the purposes for which it is collected. You may contact Biogen if you would like to access your personal data or require information about the personal data that Biogen holds about you. You may object to the processing of your personal data for legitimate reasons and you may also request the correction or erasure of it. Should you feel it necessary, you also have the right to lodge a complaint with your data protection authority. If you have questions about our processing of your personal data, you can contact Biogen's Data Protection Officer at privacy@biogen.com.